Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Palatin Technologies, Inc. Common Stock(PTN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PTN
10/19/2026: PTN (1-star) is currently NOT-A-BUY. Pass it for now.
Palatin Technologies is a biopharmaceutical company focused on developing targeted peptide therapeutics for unmet medical needs, with its primary asset being the FDA-approved drug Vyleesi. The company's main strengths lie in its proprietary melanocortin receptor technology and its history of successful clinical navigation. Its primary growth opportunity rests on advancing pipeline candidates, such as PL9643 for dry eye disease, into larger markets. Risks remain high, particularly regarding financial sustainability, intense competition from well-capitalized firms, and the binary outcomes of clinical trials. The stock is best suited for growth-oriented investors who can tolerate high volatility and should monitor clinical development milestones and potential licensing partnerships closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth investors may find interest in the potential of the clinical pipeline, though the path to sustainable, high-growth revenue remains speculative. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may be attracted to periods of high volatility surrounding clinical trial data readouts and regulatory news. |
| Value investor | Weak fit | The company is not currently profitable and does not have a traditional valuation basis, making it a poor fit for value-oriented strategies. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on capital reinvestment. |
| Low-risk investor | Weak fit | The high degree of clinical, regulatory, and financial risk makes this stock unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant price swings based on clinical trial results and financing news. |
| Valuation risk | Medium / high | Valuation is highly speculative and based on the potential success of future clinical products rather than current earnings. |
| Competition risk (Pharmaceutical) | High | The company competes with much larger entities in highly crowded therapeutic areas. |
| Business quality | Medium | While the technology platform is proprietary, the company has not yet demonstrated consistent profitability. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | High | Success depends on effectively navigating long, complex, and uncertain clinical and regulatory processes. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -40.59% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/19/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.72M USD | Price to earnings Ratio - | 1Y Target Price 53.5 |
Price to earnings Ratio - | 1Y Target Price 53.5 | ||
Volume (30-day avg) 64.5K shares | Beta -0.01 | 52 Weeks Range 5.55 - 31.00 | Updated Date 10/18/2026 |
52 Weeks Range 5.55 - 31.00 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.96 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Direct sales of Vyleesi (bremelanotide) in the US market. | The company earns money directly from patients using its approved sexual health treatment. |
| Licensing and Royalties | Upfront payments, milestone payments, and potential royalties from regional partners licensed to sell Vyleesi or other candidates. | The company partners with other firms to sell its drugs in specific regions, generating revenue without bearing all commercial costs. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 42.92 | Enterprise Value 8.40M | Price to Sales(TTM) 0.81 |
Enterprise Value 8.40M | Price to Sales(TTM) 0.81 | ||
Enterprise Value to Revenue 0.66 | Enterprise Value to EBITDA 0.55 | Shares Outstanding 1.78M | Shares Floating 1.49M |
Shares Outstanding 1.78M | Shares Floating 1.49M | ||
Percent Insiders 8.11 | Percent Institutions 50.11 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.